Inspire Medical Systems INSP
- Market cap
- $1.9B
- PE
- 14.5×
- 2y median 56.6×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.2×
- EV/EBIT
- 30.5×
- Revenue, 12 months
- $880.9M
- −0% on a year ago
- Net margin
- 15.0%
- Free cash flow yield
- 6.0%
Inspire Medical Systems trades at 14.5× trailing earnings, cheaper than 78% of the last ten years. Revenue was $880.9M over the last twelve months, down 0% on a year earlier with a 15% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $192.5M+40% | $164M+28% | $195.9M+30% | $203.2M+33% | $239.7M+25% | $201.3M+23% | $217.1M+11% | $224.5M+11% | $269.1M+12% | $204.6M+2% | $200.6M−8% | $206.7M−8% | |
| Cost of revenue | $28.1M+27% | $24.8M+25% | $29.8M+23% | $32.4M+33% | $36M+28% | $30.7M+24% | $34.7M+16% | $31.8M−2% | $36.1M+0% | $27.7M−10% | $29.1M−16% | $28.8M−9% |
| Gross profit | $164.5M+42% | $139.3M+29% | $166M+31% | $170.8M+33% | $203.7M+24% | $170.6M+23% | $182.4M+10% | $192.7M+13% | $233M+14% | $176.9M+4% | $171.5M−6% | $177.9M−8% |
| R&D | $31.1M+46% | $28.9M+13% | $28.9M−6% | $26.1M−11% | $30.3M−2% | $27.8M−4% | $26.2M−9% | $24.2M−7% | $24.9M−18% | $25.8M−7% | $24.7M−6% | $22.2M−8% |
| SG&A | $124.1M+31% | $125.6M+23% | $132.1M+17% | $130.4M+15% | $141.5M+14% | $144.3M+15% | $159.5M+21% | $158.9M+22% | $162M+14% | $152.2M+6% | $147.3M−8% | $184.4M+16% |
| $9.3M | −$15.2M−22% | $5.1M | $14.3M | $31.9M+243% | −$1.5M−90% | −$3.3M | $9.6M−33% | $46.1M+45% | −$1.1M−25% | −$514K−85% | −$28.7M | |
| Interest expense | $0 | n/a | $0 | $0 | $22K | n/a | $4K | $11K | $122K+455% | n/a | n/a | n/a |
| Pre-tax income | $15.2M+365% | −$9.4M−39% | $10.8M | $20.3M | $36.6M+140% | $4.2M | −$2.3M | $13.6M−33% | $50.3M+37% | $2.4M−42% | $3.1M | −$25M |
| $477K+282% | $650K+201% | $1.1M+392% | $1.8M+438% | $1.4M+196% | $1.2M+80% | $1.3M+20% | $3.6M+98% | −$85.8M | $13.7M+1073% | $2.8M+122% | −$616K | |
| Net income | $14.8M+369% | −$10M−35% | $9.8M | $18.5M | $35.2M+139% | $3M | −$3.6M | $9.9M−46% | $136.1M+286% | −$11.3M | $314K | −$24.4M |
| $0.50+355% | −$0.34−36% | $0.32 | $0.60 | $1.16+132% | $0.10 | −$0.12 | $0.34−43% | $4.66+302% | −$0.39 | $0.01 | −$0.84 | |
| 29.5M+2% | 29.6M+2% | 30.4M+4% | 30.6M+4% | 30.5M+3% | 30.3M+2% | 29.5M−3% | 29.6M−3% | 29.2M−4% | 28.7M−5% | 28.9M−2% | 28.9M−2% |
EPS, diluted: 6 periods, Q4 FY17 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 5 periods, Q4 FY17 to Q4 FY21: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 4 periods, Q4 FY22 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Inspire Medical Systems' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| INSPInspire Medical Systems | $1.9B | 14.5× | 56.6× | 2.2× | −0% | 15.0% | |
| LMATLemaitre Vascular | $1.9B | 28.5× | 42.0× | 7.1× | +12% | 25.0% | |
| UFPTUFP Technologies | $2.2B | 30.6× | 25.6× | 3.5× | +7% | 11.4% | |
| EYENational Vision | $1.4B | 28.1× | 52.7× | 0.7× | +8% | 2.5% | |
| CDRECadre | $1.3B | 38.9× | 35.9× | 2.0× | +20% | 5.3% | |
| WRBYWarby Parker | $2.9B | 341× | 359× | 3.2× | +11% | 0.8% | |
| STAAStaar Surgical | $1.3B | 356× | 144× | 3.7× | +51% | 1.1% | |
| ATRCAtriCure | $3B | 285× | 61.7× | 5.3× | +14% | 1.9% | |
| BVSBioventus | $1.1B | 17.1× | 27.1× | 1.9× | +4% | 9.4% | |
| IARTIntegra Lifesciences | $1.1B | 80.1× | 46.3× | 0.6× | +1% | 0.8% | |
| IRMDIradimed | $1B | 42.5× | 41.5× | 11.4× | +11% | 26.8% | |
| Peer median | $1.4B | 40.7× | 44.1× | 3.4× | +11% | 3.9% |
More on Inspire Medical Systems
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #10of 135Healthcare stocks with the fastest earnings growth
- #3of 32Medical instruments and supplies stocks with the fastest earnings growth
- #5of 35Medical instruments and supplies stocks with the lowest PE ratio
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .